Online citations, reference lists, and bibliographies.
← Back to Search

A Controlled Trial Comparing Continued Zidovudine With Didanosine In Human Immunodeficiency Virus Infection. The NIAID AIDS Clinical Trials Group.

J. Kahn, S. Lagakos, D. Richman, A. Cross, C. Pettinelli, S. Liou, M. Brown, P. Volberding, C. Crumpacker, G. Beall
Published 1992 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
BACKGROUND Although zidovudine is effective in patients with human immunodeficiency virus (HIV) infection, its efficacy may decline with prolonged use. Didanosine is another inhibitor of HIV reverse transcriptase. We evaluated the effectiveness of changing anti-HIV treatment from zidovudine to didanosine. METHODS This multicenter, double-blind study involved 913 patients who had tolerated zidovudine for at least 16 weeks. The patients had the acquired immunodeficiency syndrome (AIDS), AIDS-related complex with less than or equal to 300 CD4 cells per cubic milliliter, or asymptomatic HIV infection with less than or equal to 200 CD4 cells per cubic milliliter. They were randomly assigned to receive 600 mg per day of zidovudine, 750 mg per day of didanosine, or 500 mg per day of didanosine. RESULTS There were significantly fewer new AIDS-defining events and deaths among the 298 subjects assigned to 500 mg per day of didanosine than among the subjects who continued to receive zidovudine (relative risk, 1.39; 95 percent confidence interval, 1.06 to 1.82; P = 0.015). With 750 mg of didanosine, there was no clear benefit over zidovudine (relative risk, 1.10; 95 percent confidence interval, 0.86 to 1.42). The efficacy of didanosine was unrelated to the duration of previous zidovudine treatment. In the two didanosine groups, there were improvements in the number of CD4 cells (P less than 0.001 for both groups) and in p24 antigen levels (P = 0.03 in the 500-mg group; P = 0.005 in the 750-mg group), as compared with the zidovudine group. CONCLUSIONS Changing treatment from zidovudine to 500 mg per day of didanosine appears to slow the progression of HIV disease.
This paper references
10.1038/bjc.1977.1
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
R. Peto (1977)
10.2307/2530581
The Statistical Analysis of Failure Time Data.
M. Aitkin (1981)
10.1126/SCIENCE.6324345
Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.
M. Sarngadharan (1984)
10.1073/PNAS.82.20.7096
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
H. Mitsuya (1985)
10.1093/BIOMET/72.2.359
Combining dependent tests with incomplete repeated measurements
Lee-Jen Wei (1985)
10.1073/PNAS.83.6.1911
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.
H. Mitsuya (1986)
10.1056/NEJM198707233170401
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
M. Fischl (1987)
10.1073/PNAS.84.7.2033
Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.
H. Mitsuya (1987)
10.1056/nejm198707233170402
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
D. Richman (1987)
10.1093/INFDIS/158.5.1079
The AIDS dementia complex.
R. Price (1988)
10.1097/00002030-198907000-00001
Isolation of drug‐resistant variants of HIV‐1 from patients on long‐term zidovudine therapy
R. Rooke (1989)
10.1126/SCIENCE.2479983
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
B. Larder (1989)
10.1056/NEJM198911233212113
Bone marrow toxicity of dideoxyinosine.
J. M. Molina (1989)
10.1126/SCIENCE.2502840
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine.
R. Yarchoan (1989)
10.1126/SCIENCE.2467383
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
B. Larder (1989)
10.1056/NEJM198909143211106
Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.
R. Yarchoan (1989)
10.1001/JAMA.262.17.2405
Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. AZT Collaborative Working Group.
M. Fischl (1989)
10.1002/SIM.4780091204
Adjusting for early treatment termination in comparative clinical trials.
S. Lagakos (1990)
Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.
D. Richman (1990)
10.1093/INFDIS/161.2.326
Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS.
S. Land (1990)
10.1056/NEJM199005103221902
Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.
T. Cooley (1990)
10.1016/0140-6736(90)93391-2
Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy
C.A.B. Boucher (1990)
10.7326/0003-4819-112-10-727
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial
M. Fischl (1990)
10.1056/NEJM199010113231501
A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome
M. Fischl (1990)
10.1056/NEJM199004053221401
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
P. Volberding (1990)
10.1056/NEJM199005103221901
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
J. Lambert (1990)
10.1016/0002-9343(90)90414-9
Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.
D. Richman (1990)
10.1016/0140-6736(90)92085-V
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex
R. Yarchoan (1990)
10.1172/JCI115217
Inhibition of immune functions by antiviral drugs.
W. Heagy (1991)
10.1016/0140-6736(91)90414-K
Effect of zidovudine and Pneumocystis carinii pneumonia prophylaxis on progression of HIV-1 infection to AIDS
N.M.H. Graham (1991)
10.1212/WNL.41.6.778
Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus‐type 1 (HIV‐1) infection
R. Janssen (1991)
10.1056/NEJM199204163261601
The effects on survival of early treatment of human immunodeficiency virus infection.
N. Graham (1992)
10.1056/NEJM199202133260703
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study.
J. Hamilton (1992)



This paper is referenced by
10.1016/j.ymeth.2021.01.003
Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays
Yash Gupta (2021)
10.3390/biomedicines9080987
Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
Ruxandra Marin (2021)
10.1080/17512433.2020.1782737
The crosstalk between antiretrovirals pharmacology and HIV drug resistance
A. Giacomelli (2020)
10.3390/v10040211
Gemcitabine and Nucleos(t)ide Synthesis Inhibitors Are Broad-Spectrum Antiviral Drugs that Activate Innate Immunity
Hye Jin Shin (2018)
10.1097/EDE.0000000000000687
Mediation Analysis for Censored Survival Data Under an Accelerated Failure Time Model
I. Fulcher (2017)
10.1177/1073110517737538
Studying Effects of Medical Treatments: Randomized Clinical Trials and the Alternatives
S. Ellenberg (2017)
Aging and comorbidity among HIV-infected individuals
Dahlerup Rasmussen (2017)
10.1080/10485252.2017.1303056
Rank regression in order restricted randomised designs
J. Gao (2017)
BCX 4430 — A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease
Raymond Taylora (2016)
10.1016/j.jiph.2016.04.002
BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease
R. Taylor (2016)
Approach to the Random Effects Model
Ken P. Kleinman (2016)
Clinical Pharmacology of Antibiotics
M. Scheld (2016)
10.23937/2469-567X/1510018
Nucleoside Reverse Transcriptase Inhibitor (NRTI) Associated Macrocytosis
Wesley D Kufel (2016)
R esearch A rticle ABNORMALITIES OF SERUM AMYLASE LEVELS IN HIV SEROPOSITVE PATIENTS * Dr. Chandra Mohan , V. , Dr. Viswa Kumar , R. , Dr. Chuhitha , S. and Dr. Umapallavi
Rajiv Gandhi (2015)
Latency, expression and splicing during infection with HIV
S. Sherrill-Mix (2015)
10.1016/B978-0-12-411508-8.00010-4
Chapter 10 – Translational Medicine and Biomarkers
B. Blass (2015)
10.1093/jac/dku516
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial.
J. Moltó (2015)
PhD thesis Non-HIV determinants of outcome in Danish HIV-infected patients: Impact of study participation, body fat distribution and family-related factors
J. Gerstoft (2015)
10.1016/B978-0-7020-6285-8.00152-0
Drugs for HIV infection.
Benjamin Eckhardt (2014)
10.1080/03610926.2011.624246
Inference Based on General Linear Models for Order Restricted Randomization
O. Ozturk (2013)
10.1186/1742-4690-10-82
Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention
R. Gupta (2013)
HIV á Íslandi 1983-2012
Hlynur Indriðason (2013)
10.1007/978-1-4614-7291-9_1
Development of the First AIDS Drugs: AZT and Other Dideoxynueosides
R. Yarchoan (2013)
THE EFFECTS OF ANTIRETROVIRAL DRUGS ON CD4 CELLS IN HIV POSITIVE PATIENTS ATTENDING NAKURU GENERAL HOSPITAL, KENYA
Jane N. Mugwe (2013)
10.2165/00019053-199610020-00001
Current Controversies in the Treatment of HIV Infection and AIDS
S. Petrou (2012)
10.3968/J.PAM.1925252820120402.S0803
Robust Inference for Incomplete Binary Longitudinal Data
S. Sinha (2012)
10.2165/00019053-199610020-00002
Combination Antiretroviral Therapy in HIV Infection
R. Moore (2012)
10.2165/00003495-199855030-00005
Antiretroviral Therapy for HIV Infection
G. Moyle (2012)
10.2165/00003495-199345050-00002
Antiviral Therapy in Human Immunodeficiency Virus Infections
E. Sandström (2012)
10.1007/S00184-011-0359-3
Robust analysis of longitudinal data with nonignorable missing responses
S. Sinha (2012)
10.2165/11587480-000000000-00000
Cost Effectiveness of Darunavir/Ritonavir 600/100mg bid in Protease Inhibitor-Experienced, HIV-1-Infected Adults in Belgium, Italy, Sweden and the UK
K. Moeremans (2012)
10.2165/00003495-199500491-00003
Perspectives in Drug Therapy of HIV Infection
J. Darbyshire (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar